LSP raises €410m for sixth flagship fund

LSP 6 backs early- to late-stage drug and technology development companies. The fund has raised €410m, up 65% from its predecessor fund LSP 5 (€250m).

The fund has surpassed its original €400m target and is expected to hold a final close in H1 2019, a spokesperson for LSP told Unquote. 

The Netherlands-based life sciences specialist has now raised €750m across three funds in the past year. LSP Health Economics Fund 2 (LSP HEF 2) held a final close in December 2017, raising €280m, beating its target of €150m and coming in 150% larger than LSP HEF 1 (€110m). The fund invests in late-stage medical technology companies with products that improve quality of care and help control healthcare spending.

Meanwhile the capital under management for LSP Life Sciences Fund – an open-ended fund quoted on Euronext and investing in listed small- to mid-cap healthcare companies – and for several private mandates with the same strategy is now approaching €200m. Assets under management have nearly doubled in the past year, according to LSP.

The firm has assets under management in excess of €2bn across nine funds. Headquartered in Amsterdam, LSP also has offices in Munich and Boston. The firm invests in the Benelux and German speaking regions as well as in the US.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Benelux
• Venture
• Netherlands
• Life Science Partners